The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients

[1]Schmechel D, Marangos PJ, Brightman M. Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature 1978; 276: 834-6.SchmechelDMarangosPJBrightmanMNeurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cellsNature1978276834610.1038/276834a031568Search in Google Scholar

[2]Kimura N, Funakoshi A, Aunis D, Tateishi K, Miura W, Nagura H. Immunohistochemical localization of chromostatin and pancreastatin, chromogranin A-derived bioactive peptides, in Normal and Neoplastic Neuroendocrine Tissues. Endocr Pathol 1995; 6: 35-43.KimuraNFunakoshiAAunisDTateishiKMiuraWNaguraHImmunohistochemical localization of chromostatin and pancreastatin, chromogranin A-derived bioactive peptides, in Normal and Neoplastic Neuroendocrine TissuesEndocr Pathol19956354310.1007/BF0291498712114688Search in Google Scholar

[3]Wiedenmann B, Franke WW, Kuhn C, Moll R, Gould VE. Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci USA 1986; 83: 3500-4.WiedenmannBFrankeWWKuhnCMollRGouldVESynaptophysin: a marker protein for neuroendocrine cells and neoplasmsProc Natl Acad Sci USA1986833500410.1073/pnas.83.10.35003235443010302Search in Google Scholar

[4]May M, Siegsmund M, Hammermann F, Loy V, Gunia S. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. Scand J Urol Nephrol 2007; 41: 375-81.MayMSiegsmundMHammermannFLoyVGuniaSPrognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomyScand J Urol Nephrol2007413758110.1080/0036559070122444517853019Search in Google Scholar

[5]Krauss DJ, Amin M, Stone B, Ye H, Hayek S, Cotant M, et al. Chromogranin A staining as a prognostic variable in newly diagnosed Gleason score. Prostate 2014; 74: 520-7.KraussDJAminMStoneBYeHHayekSCotantMet al.Chromogranin A staining as a prognostic variable in newly diagnosed Gleason scoreProstate201474520710.1002/pros.2277124375481Search in Google Scholar

[6]Berruti A, Vignani F, Russo L, Bertaglia V, Tullio M, Tucci M, et al. Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle. Open Access J Urol 2010; 2: 109-24.BerrutiAVignaniFRussoLBertagliaVTullioMTucciMet al.Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzleOpen Access J Urol201021092410.2147/OAJU.S6573Search in Google Scholar

[7]Cindolo L, Cantile M, Franco R, Chiodini P, Schiavo G, Forte I, et al. Parallel determination of NeuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers. Int Braz J Urol 2011; 37: 57-66.CindoloLCantileMFrancoRChiodiniPSchiavoGForteIet al.Parallel determination of NeuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancersInt Braz J Urol201137576610.1590/S1677-5538201100010000821385481Search in Google Scholar

[8]Jeetle SS, Fisher G, Yang ZH, Stankiewicz E, Moller H, Cooper CS, et al. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer. Virchows Arch 2012; 461: 103-7.JeetleSSFisherGYangZHStankiewiczEMollerHCooperCSet al.Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancerVirchows Arch2012461103710.1007/s00428-012-1259-222767265Search in Google Scholar

[9]Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera J-M, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 2014; 38: 756-67.EpsteinJIAminMBBeltranHLotanTLMosqueraJ-MReuterVEet al.Proposed morphologic classification of prostate cancer with neuroendocrine differentiationAm J Surg Pathol2014387566710.1097/PAS.0000000000000208411208724705311Search in Google Scholar

[10]Helpap B, Kollermann J. Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch 1999; 434: 385-91.HelpapBKollermannJUndifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesisVirchows Arch19994343859110.1007/s00428005035710389621Search in Google Scholar

[11]Grobholz R, Griebe M, Sauer CG, Michel MS, Trojan L, Bleyl U. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum Pathol 2005; 36: 562-70.GrobholzRGriebeMSauerCGMichelMSTrojanLBleylUInfluence of neuroendocrine tumor cells on proliferation in prostatic carcinomaHum Pathol2005365627010.1016/j.humpath.2005.02.01915948124Search in Google Scholar

[12]Gunia S, Albrecht K, Koch S, Herrmann T, Ecke T, Loy V, et al. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible interobserver variability. World J Urol 2008; 26: 243-50.GuniaSAlbrechtKKochSHerrmannTEckeTLoyVet al.Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible interobserver variabilityWorld J Urol2008262435010.1007/s00345-008-0257-018392627Search in Google Scholar

[13]Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 2014; 20: 2846-50.BeltranHTomlinsSAparicioAAroraVRickmanDAyalaGet al.Aggressive variants of castration-resistant prostate cancerClin Cancer Res20142028465010.1158/1078-0432.CCR-13-3309404031624727321Search in Google Scholar

[14]Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.GerdesJSchwabULemkeHSteinHProduction of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferationInt J Cancer198331132010.1002/ijc.29103101046339421Search in Google Scholar

[15]Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011; 103: 1656-64.DowsettMNielsenTOA’HernRBartlettJCoombesRCCuzickJet al.Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJ Natl Cancer Inst201110316566410.1093/jnci/djr393321696721960707Search in Google Scholar

[16]Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105: 1550-7.IkenbergHBergeronCSchmidtDGriesserHAlamedaFAngeloniCet al.Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS studyJ Natl Cancer Inst20131051550710.1093/jnci/djt235381441124096620Search in Google Scholar

[17]Li R, Heydon K, Hammond ME, Grignon DJ, Roach M 3rd, Wolkov HB, et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res 2004; 10: 4118-24.LiRHeydonKHammondMEGrignonDJRoachM3rdWolkovHBet al.Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10Clin Cancer Res20041041182410.1158/1078-0432.CCR-1052-0315217948Search in Google Scholar

[18]Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 2004; 22: 2133-40.PollackADeSilvioMKhorLYLiRAl-SaleemTIHammondMEet al.Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02J Clin Oncol20042221334010.1200/JCO.2004.09.15015169799Search in Google Scholar

[19]Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009; 100: 888-93.BerneyDMGopalanAKudahettiSFisherGAmbroisineLFosterCSet al.Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group studyBr J Cancer20091008889310.1038/sj.bjc.6604951266177819293807Search in Google Scholar

[20]Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol 2009; 27: 3177-84.KhorLYBaeKPaulusRAl-SaleemTHammondMEGrignonDJet al.MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02J Clin Oncol20092731778410.1200/JCO.2008.19.8267271693919470936Search in Google Scholar

[21]Fisher G, Yang ZH, Kudahetti S, Møller H, Scardino P, Cuzick J, et al. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort. Br J Cancer 2013; 108: 271-7.FisherGYangZHKudahettiSMøllerHScardinoPCuzickJet al.Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohortBr J Cancer2013108271710.1038/bjc.2012.598356681123329234Search in Google Scholar

[22]Verhoven B, Yan Y, Ritter M, Khor LY, Hammond E, Jones C, et al. Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08. Int J Radiat Oncol Biol Phys 2013; 86: 317-23.VerhovenBYanYRitterMKhorLYHammondEJonesCet al.Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08Int J Radiat Oncol Biol Phys2013863172310.1016/j.ijrobp.2013.01.016364697423474109Search in Google Scholar

[23]Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach AC, Meistrich ML, et al. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 2002; 8: 1148-54.CowenDTroncosoPKhooVSZagarsGKvonEschenbach ACMeistrichMLet al.Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapyClin Cancer Res20028114854Search in Google Scholar

[24]Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008; 122: 595-602.LaitinenSMartikainenPMTolonenTIsolaJTammelaTLVisakorpiTEZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patientsInt J Cancer200812259560210.1002/ijc.2314517943722Search in Google Scholar

[25]Zellweger T, Günther S, Zlobec I, Savic S, Sauter G, Moch H, et al. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 2009; 124: 2116-23.ZellwegerTGüntherSZlobecISavicSSauterGMochHet al.Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancerInt J Cancer200912421162310.1002/ijc.2417419117060Search in Google Scholar

[26]Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 2012; 118: 6063-71.AntonarakisESKeizmanDZhangZGurelBLotanTLHicksJLet al.An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomyCancer201211860637110.1002/cncr.27689357253422674438Search in Google Scholar

[27]Rubio J, Ramos D, López-Guerrero JA, Iborra I, Collado A, Solsona E, et al. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 2005; 48: 745-51.RubioJRamosDLópez-GuerreroJAIborraIColladoASolsonaEet al.Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimensEur Urol2005487455110.1016/j.eururo.2005.06.01416139948Search in Google Scholar

[28]Pascale M, Pracella D, Barbazza R, Marongiu B, Roggero E, Bonin S, et al. Is human papillomavirus associated with prostate cancer survival? Dis Markers 2013; 35: 607-13.PascaleMPracellaDBarbazzaRMarongiuBRoggeroEBoninSet al.Is human papillomavirus associated with prostate cancer survival?Dis Markers2013356071310.1155/2013/735843383078424288430Search in Google Scholar

[29]Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003; 55: 20-9.ZellwegerTNinckCMirlacherMAnnefeldMGlassAGGasserTCet al.Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancerProstate20035520910.1002/pros.1020912640657Search in Google Scholar

[30]Surcel CI, van Oort IM, Sooriakumaran P, Briganti A, De Visschere PJL, Futterer JJ, et al. Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review. Urol Oncol 201; 33: 265.e1-7.SurcelCIvan OortIMSooriakumaranPBrigantiADe VisscherePJLFuttererJJet al.Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical reviewUrol Oncol20133265.e1710.1016/j.urolonc.2014.08.00725238700Search in Google Scholar

[31]Hirano D, Jike T, Okada Y, Minei S, Sugimoto S, Yamaguchi K, et al. Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the prostate: an immunoelectron microscopic study. Ultrastruct Pathol 2005; 29: 367-75.HiranoDJikeTOkadaYMineiSSugimotoSYamaguchiKet al.Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the prostate: an immunoelectron microscopic studyUltrastruct Pathol2005293677510.1080/01913129094571816257863Search in Google Scholar

[32]Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004; 45: 586-92. discussion 592.HiranoDOkadaYMineiSTakimotoYNemotoNNeuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapyEur Urol20044558692discussion 59210.1016/j.eururo.2003.11.032Search in Google Scholar

[33]Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012; 30: e386-9.BeltranHTagawaSTParkKMacDonaldTMilowskyMIMosqueraJMet al.Challenges in recognizing treatment-related neuroendocrine prostate cancerJ Clin Oncol201230e386910.1200/JCO.2011.41.5166Search in Google Scholar

[34]Komiya A, Yasuda K, Watanabe A, Fujiuchi Y, Tsuzuki T, Fuse H. The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients. Mol Clin Oncol 2013; 1: 257-62.KomiyaAYasudaKWatanabeAFujiuchiYTsuzukiTFuseHThe prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patientsMol Clin Oncol201312576210.3892/mco.2013.69Search in Google Scholar

[35]Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw 2014; 12: 719-26.AggarwalRZhangTSmallEJArmstrongAJNeuroendocrine prostate cancer: subtypes, biology, and clinical outcomesJ Natl Compr Canc Netw2014127192610.6004/jnccn.2014.0073Search in Google Scholar

[36]Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-Octreotate. J Nucl Med 2014; 55: 183-90.EzziddinSAttassiMYong-HingCJAhmadzadehfarHWillinekWGrünwaldFet al.Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-OctreotateJ Nucl Med2014551839010.2967/jnumed.113.125336Search in Google Scholar

[37]Pelosi G, Rindi G, Travis WD, Papotti M. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol 2014; 9: 273-84.PelosiGRindiGTravisWDPapottiMKi-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practiceJ Thorac Oncol201492738410.1097/JTO.0000000000000092Search in Google Scholar

[38]Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013; 15: 1-10.MosqueraJMBeltranHParkKMacDonaldTYRobinsonBDTagawaSTet al.Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancerNeoplasia20131511010.1593/neo.121550Search in Google Scholar

[39]Khoo VS, Pollack A, Cowen D, Joon DL, Patel N, Terry NH, et al. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 1999; 41: 166-72.KhooVSPollackACowenDJoonDLPatelNTerryNHet al.Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapyProstate1999411667210.1002/(SICI)1097-0045(19991101)41:3<166::AID-PROS3>3.0.CO;2-ESearch in Google Scholar

[40]Nagao K, Yamamoto Y, Hara T, Komatsu H, Inoue R, Matsuda K, et al. Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range < 4 ng/ml. Jpn J Clin Oncol 2011; 41: 555-64.NagaoKYamamotoYHaraTKomatsuHInoueRMatsudaKet al.Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range < 4 ng/mlJpn J Clin Oncol2011415556410.1093/jjco/hyq233Search in Google Scholar

[41]Zhao L, Yu N, Guo T, Hou Y, Zeng Z, Yang X, et al. Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014; 23: 1047-54.ZhaoLYuNGuoTHouYZengZYangXet al.Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysisCancer Epidemiol Biomarkers Prev20142310475410.1158/1055-9965.EPI-13-0696Search in Google Scholar